Physician profile
Win Myint
NPI 1063412062
$22,343.27
in general payments reported to CMS, 2019-2025
53 companies · $2,326 in 2025
The $2,326 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,088 · 2020: $3,156 · 2021: $4,065 · 2022: $3,440 · 2023: $2,576 · 2024: $2,693 · 2025: $2,326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,595.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,594.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,875.53 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,978.75 | 2019-2025 | Trelegy Ellipta |
| Pfizer INC. | $1,906.06 | 2019-2025 | |
| Lilly USA, LLC | $1,397.25 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,283.88 | 2019-2025 | |
| Novo Nordisk INC | $1,233.37 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,062.97 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $913.88 | 2019-2024 | Xarelto |
| Amgen INC. | $813.03 | 2019-2025 | Otezla, Repatha, Evenity |
| Sanofi-Aventis U.S. LLC | $804.99 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $797.20 | 2019-2024 | Verquvo, Steglatro |
| Allergan, INC. | $634.14 | 2019-2020 | |
| Astellas Pharma US INC | $566.82 | 2019-2023 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $560.92 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $452.39 | 2019-2025 | Xifaxan |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Win Myint listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.